Combined modality treatment for central nervous system malignancies

Seminars in Oncology

Volumn 30, Issue 4 SUPPL. 9, 2003, Pages 11-22

  Robins, H Ian ^b   Peterson, Christopher G ^b   Mehta, Minesh P ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; CARBOPLATIN; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DOXORUBICIN; ETIRACETAM; ETOPOSIDE; FLUOROURACIL; GABAPENTIN; GEFITINIB; LOMUSTINE; METHOTREXATE; NITROSOUREA DERIVATIVE; PACLITAXEL; PREDNISONE; PROCARBAZINE; PROTEIN KINASE C INHIBITOR; TAMOXIFEN; TEMOZOLOMIDE; TEMSIROLIMUS; TENIPOSIDE; THALIDOMIDE; TIPIFARNIB; TIRAPAZAMINE; TOPOTECAN; UNINDEXED DRUG; VALPROIC ACID; VINCRISTINE;

ASTROCYTOMA; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CENTRAL NERVOUS SYSTEM TUMOR; GLIOBLASTOMA; GLIOMA; HUMAN; LUNG CANCER; LYMPHOMA; MULTIMODALITY CANCER THERAPY; OLIGODENDROGLIOMA; PRIORITY JOURNAL; REVIEW; TESTIS CANCER;

EID: 0043238713     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0093-7754(03)00271-9     Document Type: Article

References (106)

1. Lowitz BB, Casciato DA, Tabbarah HJ: Neurologic tumor, in Casiato DA, Lowitz BB (eds): Manual of Clinical Oncology. Little, Brown, 1988, pp 220-230
2. Levin VA, Sheline GE, Gutin PH: Neoplasms of the central nervous system, in DeVita VT Jr, Hellman S, Rosenberg SA (eds): Cancer: Principles & Practice of Oncology. Lippincott, 1989, pp 557-612
3. Bloom HJ: Combined modality therapy for intracranial tumors. Cancer 35:111-120, 1975
4. Salazar OM, Rubin P, Feldstein ML, et al: High-dose radiation therapy in the treatment of malignant gliomas: Final report. Int J Radiat Oncol Biol Phys 3:1733-1740, 1979
5. Walker MD, Strike TA, Sheline GE: An analysis of dose-effect relationship in the radiotherapy of malignant gliomas. Int J Radiat Oncol Biol Phys 5:1725-1731, 1979
6. Scanlon PW, Taylor WF: Radiotherapy of intracranial astrocytomas: Analysis of 417 cases treated from 1960 through 1969. Neurosurgery 5:301-308, 1979
7. Sheline GE: Radiation therapy of brain tumors. Cancer 39:873-881, 1977
8. Loeffler JS, Patchell RA, Sawaya R: Treatment of metastatic cancer, in DeVita VT Jr, Hellman S, Rosenberg SA (eds): Cancer: Principles & Practice of Oncology. Lippincott-Raven, 1997, pp 2523-2536
9. Bindal RK, Sawaya R, Leavens ME, et al: Surgical treatment of multiple brain metastases. J Neurosurg 79:210-216, 1993
10. Noordijk EM, Vecht CJ, Haaxma-Reiche H, et al: The choice of treatment of single brain metastasis should be based on extracranial tumor activity and age. Int J Radiat Oncol Biol Phys 29:711-717, 1994
11. Cooia LR: The role of radiation therapy in the treatment of brain metastases. Int J Radiat Oncol Biol Phys 23:229-238, 1992
12. DeAngelis LM, Delattre JY, Posner JB: Radiation-induced dementia in patients cured of brain metastases. Neurology 39:89-96, 1989
13. Brady LW, Mancall EL, Lee DK, et al: Radiation therapy for intracranial metastatic neoplasia. Radiol Clin Biol 43:40-47, 1974
14. Le Chevalier T, Smith FP, Caille P, et al: Sites of primary malignancies in patients presenting with cerebral metastases: A review of 120 cases. Cancer 56:880-882, 1985
15. Eby NL, Grufferman S, Flannelly CM, et al: Increasing incidence of primary brain lymphoma in the U.S. Cancer 62:2461-2465, 1988
16. Corn BW, Marcus SM, Topham A, et al: Will primary central nervous system lymphoma be the most frequent brain tumor diagnosed in the year 2000? Cancer 79:2409-2413, 1997
17. Coté TR, Manns A, Hardy CR, et al: Epidemiology of brain lymphoma among people with or without acquired immunodeficiency syndrome. J Natl Cancer Inst 88:675-679, 1996
18. Glioma Meta-analysis Trialists (GMT) Group: Chemotherapy in adult high-grade glioma: A systematic review and meta-analysis of individual patient data from 12 randomized trials. Lancet 359:1011-1018, 2002
19. Hess KR, Wong ET, Jaeckle KA, et al: Response and progression in recurrent malignant glioma. Neuro-Oncology 1:282-288, 1999
20. Graham PH: Meta-analysis of radiation therapy with or without adjuvant chemotherapy for malignant gliomas in adults. Cancer 72:3367, 1993
21. Fine HA, Dear KBG, Loeffler JS, et al: Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer 71:2585-2597, 1993
22. Walker MD, Alexander E, Hunt WE, et al: Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. J Neurosurg 49:333-343, 1978
23. Walker MD, Green SB, Byar DP, et al: Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med 303:1323-1329, 1980
24. Levin VA, Kabra P: Effectiveness of the nitrosoureas as a function of their lipid solubility in the chemotherapy of experimental rat brain tumors. Cancer Chemother Rep 58:787-792, 1974
25. Galanis E, Buckner J: Chemotherapy for high-grade gliomas. Br J Cancer 82:1371-1380, 2000
26. DeAngelis LM: Brain tumors. N Engl J Med 344:114-123, 2001
27. Seiferheld W, Mehta MP, Delrowe J, et al: Five years of glioblastoma multiforme (GBM) phase II trials at the RTOG. Proc Am Soc Clin Oncol 21:71a, 2002 (abstr 281)
28. Curran WJ Jr, Scott CB, Horton J, et al: Recursive partitioning analysis of prognostic factors in three RTOG malignant glioma trials. J Natl Cancer Inst 85:704-710, 1993
29. Scott CB, Scarantino C, Urtasun R, et al: Validation and predictive power of RTOG recursive partitioning analysis classes for malignant glioma patients: A report using RTOG 90-96. Int J Radiat Oncol Biol Phys 40:51-55, 1998
30. Denny BJ, Wheelhouse RT, Stevens MFG, et al: NMR and molecular modeling investigation of the mechanism and activation of the antitumor drug temozolomide and its interaction with DNA. Biochemistry 33:9045-9051, 1994
31. Yung WK, Prados MD, Yaya-Tur R, et al: Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. J Clin Oncol 17:2762-2771, 1999
32. van Rijn J, Heimans JJ, van den Berg J, et al: Survival of human glioma cells treated with various combinations of temozolomide and x-rays. Int J Radiat Oncol Biol Phys 47:779-784, 2000
33. Wedge SR, Porteous JK, Glaser MG, et al: In vitro evaluation of temozolomide combined with X-irradiation. Anticancer Drugs 8:92-97, 1997
34. Stupp R, Dietrich P-Y, Kralijevic SO, et al: Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol 20:1375-1382, 2002
35. Gilbert M, Olson J, Yung WKA, et al: Procarbazine, lomustine, pre-radiation treatment of newly diagnosed anaplastic astrocytomas and glioblastoma multiforme using temozolomide. Neuro-Oncol 2:264, 2000 (abstr 77)
36. Prados MD, Scott C, Curran WJ, et al: Procarbazine, lomustine, and vincristine (PCV) chemotherapy for anaplastic astrocytoma: A retrospective review of Radiation Therapy Oncology Group protocols comparing survival with carmustine or PCV adjuvant chemotherapy. J Clin Oncol 17:3389-3395, 1999
37. Levin VA, Leibel SA, Gutin PH: Neoplasms of the central nervous system, in DeVita VT Jr, Hellman S, Rosenberg SA, (eds): Cancer: Principles & Practice of Oncology. Lippincott-Raven, 1997, pp 2022-2082
38. Chamberlain MC, Kormanik PA: Practical guidelines for the treatment of malignant gliomas. West J Med 168:114-120, 1998
39. Medical Research Council Brain Tumour Working Party: Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma: A Medical Research Council trial. J Clin Oncol 19:509-518, 2001
40. Grossman SA, Wharam M, Sheidler V, et al: Phase II study of continuous infusion carmustine and cisplatin followed by cranial irradiation in adults with newly diagnosed high-grade astrocytoma. J Clin Oncol 15:2596-2603, 1997
41. Gilbert M, O'Neill A, Grossman SA, et al: A phase II study of preradiation chemotherapy followed by external beam radiotherapy for the treatment of patients with newly diagnosed glioblastoma multiforme: An Eastern Cooperative Oncology Group study (E2393). J Neuro Oncol 47:145-152, 2000
42. Grossman SA, O'Neil A, Grunnet M, et al: Phase III study comparing three cycles of infusional BCNU/cisplatin followed by radiation with radiation and concurrent BCNU for patients with newly diagnosed supratentorial glioblastoma multiforme (ECOG 2394-SWOG 9503). Proc Am Soc Clin Oncol 19:158a, 2000 (abstr 612)
43. Kim L, Hochberg F, Thornton A, et al: Procarbazine, lomustine, and vincristine (PCV) chemotherapy for grades III and IV oligoastrocytomas. J Neurosurg 85:602-607, 1996
44. Cairncross G, MacDonald D, Ludwin S, et al: Chemotherapy for anaplastic oligodendroglioma. J Clin Oncol 12: 2013-2021, 1994
45. Smith J, Perry A, Borell T, et al: Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J Clin Oncol 18:636-664, 2000
46. Cairncross JG, Ueki K, Zlatescu MC, et al: Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 90:1473-1479, 1998
47. Chinot OL, Honore S, Dufour H, et al: Safety and efficacy of temozolomide in patients with recurrent anaplastic oligodendrogliomas after standard radiotherapy and chemotherapy. J Clin Oncol 19:2449-2455, 2001
48. vanden Bent MJ, Taphoorn MJB, Brandes AA, et al: EORTC brain tumor group study 26971-First line chemotherapy with temozolomide in recurrent oligodendroglial tumors; A phase II study. Proc Am Soc Clin Oncol 21:72a, 2002 (abstr 285)
49. Groves M, Puduvalli V, Hess K, et al: Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme. J Clin Oncol 20:1383-1388, 2002
50. Robins HI, Chang SM, Prados MD, et al: A phase II trial of thymidine and carboplatin for recurrent malignant glioma: A North American Brain Tumor Consortium Study. Neuro-Oncol 4:109-114, 2002
51. 131I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas. J Clin Oncol 20:1389-1397, 2002
52. Bogelt B, Belber R, Kramer S, et al: The palliation of brain metastases: Final results of the first two studies by the RTOG. Int J Radiat Oncol Biol Phys 6:1-9, 1980
53. Gelber R, Larson M, Borgelt B, et al: Equivalence of radiation schedules for the palliative treatment of brain metastases in patients with favorable prognosis. Cancer 48:1749-1753, 1981
54. Kurtz J, Gelber R, Brady L, et al: The palliation of brain metastases in a favorable patient population: A randomized clinical trial by the RTOG. Int J Radiat Oncol Biol Phys 7:891-895, 1981
55. Murray KJ, Scott C, Greenberg HM, et al: A randomized phase III study of accelerated hyperfractionation versus standard in patients with unresected brain metastases: A report of the RTOG 91-04. Int J Radiat Oncol Biol Phys 39:571-574, 1997
56. Phillips TL, Scott CB, Leibe SA, et al: Results of a randomized comparison of radiotherapy and bromodeoxyuridine with radiotherapy alone for brain metastases. Report of RTOG trial 89-05. Int J Radiat Oncol Biol Phys 33:339-349, 1995
57. Komarnicky LT, Phillips TL, Martz K, et al: A randomized phase III protocol for the evaluation of misonidazole combined with radiation in the treatment of patients with brain metastases (RTOG-7916). Int J Radiat Oncol Biol Phys 20:53-58, 1991
58. Wronski M, Arbit E, Burt M, et al: Survival after surgical treatment of brain metastases from lung cancer: A follow-up study of 231 patients treated between 1976 and 1991. J Neurosurg 83:605-616, 1995
59. Nieder C, Nestle U, Walter K, et al: Dose/effect relationships for brain metastases. J Cancer Res Clin Oncol 124: 346-50, 1998
60. Cascino TL, Byrne TN, Deck MD, et al: Intra-arterial BCNU in the treatment of metastatic brain tumors. J Neurol Oncol 1:211-218, 1983
61. Franciosi V, Cocconi G, Michiara M, et al: Front-line chemotherapy with cisplatin and etoposide for patients with brain metastases from breast carcinoma, non-small cell lung carcinoma, or malignant melanoma: A prospective study. Cancer 85:1599-1605, 1999
62. Fosså, SD, Bokemeyer C, Gerl A, et al: Treatment outcome of patients with brain metastases from malignant germ cell tumors. Cancer 85:988-997, 1999
63. Postmus PE, Haaxma-Reiche H, Smit EF, et al: Treatment of brain metastases of small-cell lung cancer: Comparing teniposide and teniposide with whole-brain radiotherapy. A phase III study of the European Organization for the Research and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol 18:3400-3408, 2000
64. Ushio Y, Arita N, Hayakawa T, et al: Chemotherapy of brain metastases from lung carcinoma: A controlled randomized study. Neurosurgery 28:201-205, 1991
65. Bernardo G, Cuzzoni Q, Strada MR, et al: First-line chemotherapy with vinorelbine, gemcitabine, and carboplatin in the treatment of brain metastases from non-small cell lung cancer: A phase II study. Cancer Invest 20:293-302, 2002
66. Newlands ES, O'Reilly SM, Glaser MG, et al: The Charing Cross Hospital experience with temozolomide in patients with gliomas. Eur J Cancer 32A:2236-2241, 1996
67. Newlands ES, Blackledge CR, Slack JA, et al: Phase I trial of temozolomide (CCRG 81045: M&B 39831:NSC 362856). Br J Cancer 65:287-291, 1992
68. O'Reilly SM, Newlands ES, Glaser MG, et al: Temozolomide: A new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumors. Eur J Cancer 29A:940-942, 1993
69. Yung WK, Albright RE, Olson J, et al: A phase II study of temozolomide vs procarbozine in patient with glioblastoma multiforme at first relapse. Br J Cancer 83:588-593, 2000
70. Middleton MR, Grobb JJ, Aaronson N, et al: Randomized phase III study of temozolomide versus decarbazine in the treatment of patient with advanced metastatic malignant melanoma. J Clin Oncol 18:158-166, 2000
71. Reid JM, Stevens DC, Rubin J, et al: Pharmacokinetics of 3-methyl-(triazen-1-yl) imidazole-4-carboximide following administration of temozolomide to patients with advanced cancer. Clin Cancer Res 3:2393-2398, 1997
72. Patel M, McCully C, Godwin K, et al: Plasma and cerebrospinal fluid pharmacokinetics of temozolomide. Proc Am Soc Clin Oncol 14:461a, 1995 (abstr 1485)
73. Agarwala S, Reyderman L, Statkevich P, et al: Pharmacokinetic study of temozolomide penetration into SSF in a patient with dural melanoma. Ann Oncol 9:138a, 1998 (abstr 659) (suppl 4)
74. Brada M, Judson I, Beale P, et al: Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies. Br J Cancer 81:1022-1030, 1999
75. Brock CS, Newlands ES, Wedge SR, et al: Phase I trial of temozolomide using an extended continuous oral schedule. Cancer Res 58:4363-4367, 1998
76. Antonadou D, Paraskevaides M, Sarris N, et al: Phase II randomized trial of temozolomide and concurrent radiotherapy in patients with brain metastases. J Clin Oncol 20:3644-3650, 2002
77. Dardoufas C, Miliadouo A, Skarleas C, et al: Concomitant temozolomide (TMZ) and radiotherapy (RT) followed by adjuvant treatment with temozolomide in patients with brain metastases from adjuvant treatment with temozolomide in patients with brain metastases from solid tumors. Proc Am Soc Clin Oncol 20:75b, 2001 (abstr 2048)
78. Antonadou D, Coliarakis N, Paraskevaides M, et al: Whole brain radiotherapy alone or in combination with temozolomide for brain metastases. A phase III study. Int J Radiat Oncol Biol Phys 54:93-94, 2002 (suppl 1)
79. Safo MK, Moure CM, Burnett JC, et al: High-resolution crystal structure of deoxy hemoglobin complexed with a potent allosteric effector. Protein Science 10:951-957, 2001
80. Carde P, Timmerman R, Mehta MP, et al: Multicenter phase Ib/II trial of the radiation enhancer motexafin adolinium in patients with brain metastases. J Clin Oncol 19:2074-2083, 2001
81. Mehta MP, Rodrigus P, Terhaard C, et al: Results from the phase III trial of motexafin gadolinium (MGd) in brain metastases. Proc Am Soc Clin Oncol 21:72a, 2002 (abstr 286)
82. Gaynor ER, Fisher RI: Intermediate and high grade lymphomas, in Haskell CM, Berek JS (eds): Cancer Treatment. Saunders, 2001, pp 1387-1391
83. Henry JM, Heffner RR, Dillard SH, et al: Primary malignant lymphoma of the central nervous system. Cancer 34: 1293-1302, 1974
84. Nelson DF, Martz KL, Bonner H, et al: Non-Hodgkin's lymphoma of the brain: Can high dose, large volume radiation therapy improve survival? Report on a prospective trial by the RTOG: RTOG 8315. Int J Radiat Oncol Biol Phys 23:9-17, 1992
85. Nelson DF: Radiotherapy in the treatment of primary central nervous system lymphoma (PCNSL). J Neurooncol 43:241-247, 1999
86. Lachance DH, Brizel DM, Gockerman JP, et al: Cyclophosphamide, doxorubicin, vincristine, and prednisone for primary central nervous system lymphoma: Short duration response and multifocal intracerebral recurrence preceding radiotherapy. Neurology 44:1721-1727, 1994
87. Schultz C, Scott C, Sherman W, et al: Preirradiation chemotherapy with cyclophosphamide, doxorubicin, vincristine, and dexamethasone for primary CNS lymphomas: Initial report of RTOG protocol 88-06. J Clin Oncol 14:556-564, 1996
88. O'Neill BP, Wang CH, O'Fallon JR: Primary central nervous system non-Hodgkin's lymphoma (PCNSL): Survival advantages with combined initial therapy? A final report of the North Central Cancer Treatment Group (NCCTG) study 86-72-52. Int J Radiat Oncol Biol Phys 43:559-563, 1995
89. O'Neill BP, O'Fallon JR, Earle JD, et al: Primary central nervous system non-Hodgkin's lymphoma: Survival advantages with combined initial therapy? Int J Radiat Oncol Biol Phys 33:663-673, 1995
90. Mead GM, Bleehen NM, Gregor A, et al: Medical research council (MRC) randomized trial of adjuvant chemotherapy in primary CNS lymphoma (PCL)-BR06. Proc Am Soc Clin Oncol 17:401a, 1998 (abstr 1547)
91. Roelcke U: PET: Brain tumor biochemistry. J Neurooncol 22:275-279, 1994
92. Roelke U, Leenders KL: PET in patients with primary central nervous system lymphoma. J Neurooncol 43:231-236, 1999
93. Ott RJ, Brada M, Flower MA, et al: Measurements of blood-brain barrier permeability in patients undergoing radiotherapy and chemotherapy for primary cerebral lymphoma. Eur J Cancer 27:1356-1361, 1991
94. Gabbai AA, Hochberg FH, Linsgood RM, et al: High-dose methotrexate for non-AIDS primary central nervous system lymphoma. J Neurosurg 70:190-194, 1989
95. DeAngelis LM, Yahalom J, Thaler HT, et al: Combined modality therapy for primary CNS lymphoma. J Clin Oncol 10:635-643, 1992
96. Abrey LE, DeAngelis LM, Yahalom J: Long-term survival in primary CNS lymphoma. J Clin Oncol 3:859-863, 1998
97. Glass J, Gruber ML, Cher L, et al: Preirradiation methotrexate chemotherapy of primary central nervous system lymphoma: Long-term outcome. J Neurosurg 81:188-195, 1994
98. Schultz C, Scott C, DeAngelis L, et al: Radiation therapy alone versus pre-irradiation chemotherapy for the treatment of primary CNS lymphoma: An aged matched survival analysis of RTOG 83-15 and RTOG 93-10. Proc Am Soc Clin Oncol 19:159a, 2000 (abstr 617)
99. Blay JY, Conroy T, Chevreau C, et al: High-dose methotrexate for the treatment of primary cerebral lymphomas: Analysis of survival and late neurological toxicity in a retrospective series. J Clin Oncol 16:864-871, 1998
100. Nelson DF: Radiotherapy in the treatment of primary central nervous system lymphoma. J Neurooncol 43:241-247, 1999
101. Neuwelt EA, Goldman DL, Dahlborg SA, et al: Primary CNS lymphoma treated with osmotic blood-brain barrier disruption. Prolonged survival and preservation of cognitive function. J Clin Oncol 9:1580-1590, 1991
102. Neuwelt EA, McAllister LD, Wilson DJ, et al: Non-AIDS primary CNS lymphoma (PCNSL): Is enhanced delivery important? Neuro-Oncol 1:S42, 1999 (abstr 156)
103. Neuwelt EA, Dahlborg SA, Henner WD, et al: Non-AIDS primary CNS lymphoma: The first example of a durable response in a primary brain tumor using enhanced chemotherapy delivery without cognitive loss and without radiotherapy. Proc Am Soc Clin Oncol 14:144, 1995 (abstr 271)
104. Raizer JJ, Lisa DM, Zelenetz AD, et al: Activity of rituximab in primary central nervous system lymphoma (PCNSL). Proc Am Soc Clin Oncol 19:166a, 2000 (abstr 642)
105. Ruhstaller TW, Amsler U, Cerny T: Rituximab: Active treatment of central nervous system involvement by non-Hodgkin's lymphoma? Ann Oncol 11:374-375, 2000
106. Reni M, Ferreri AJ, Landoni C, et al: Salvage therapy with temozolomide in an immunocompetent patient with primary brain lymphoma. J Natl Cancer Inst 92:575-576, 2000